EurekAlert!

Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation

SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
La Grande Observer

Hannah Storm, Award-Winning Broadcaster and DCIS Patient Advocate, Partners with PreludeDx to Share How the DCISionRT Test Gave Her Confidence in Her Treatment Decision

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...
ascopubs.org

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights

Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice In response to the 2024 data updates, ...
USA Today

Are doctors overtreating early-stage breast cancer? Is active monitoring as safe?

Cancer is typically treated with surgery, radiation and sometimes chemotherapy. But a new study suggests this standard protocol might not be necessary for a common form of early-stage breast cancer.
Medscape

Breast Cancer: Risk Assessment, Risk Reduction, and Advances in Diagnostic and Surgical Techniques

With breast cancer now afflicting nearly 1 in 7 women in the United States, it was entirely appropriate for the first annual Oncology World Congress to dedicate a plenary session to discussing ...
Morningstar

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE, Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has ...